On September 17, 2026, a federal bankruptcy judge in Texas gave final approval to Omnicare’s Chapter 11 wind-down plan — formally closing the book on what the Department of Justice called “one of the largest damages verdicts rendered by a jury in a False Claims Act case.” The resolution caps a decade-long legal odyssey that began with a single whistleblower’s qui tam complaint in 2015 and ended with a $440 million DOJ settlement, a historic jury verdict finding more than 3.3 million false claims, and a bankruptcy proceeding that reshaped long-term care pharmacy in America. For the hundreds of thousands of elderly and disabled nursing-home residents whose prescriptions were quietly “rolled over” without valid physician orders, understanding the Omnicare CVS False Claims Act lawsuit — and what it means for their rights — has never been more important.
How the Omnicare CVS False Claims Act Lawsuit Began: The Whistleblower Behind the Case
The Omnicare CVS False Claims Act lawsuit traces its origins to 2015, when former Omnicare pharmacist Uri Bassan filed a qui tam complaint under the False Claims Act on behalf of the federal government, 29 states, and the District of Columbia. Bassan alleged that from 2010 to 2018, Omnicare — then America’s largest long-term care pharmacy, operating approximately 160 pharmacies across 47 states and dispensing prescriptions to more than 800,000 patients in over 4,000 long-term care facilities — had engaged in a systematic scheme to dispense drugs without valid physician authorizations.
The practice at the center of the case was internally known as “rolling over.” According to the DOJ complaint, Omnicare’s computer system assigned new prescription numbers or reset refill counts to as many as 99 for Medicare patients, allowing pharmacists to continue dispensing expired or refill-exhausted medications without ever contacting the prescribing physician. Drugs dispensed under this scheme included antipsychotics, anticonvulsants, and antidepressants — medications with serious side-effect profiles — billed to Medicare, Medicaid, and TRICARE in more than 30 states and Washington D.C. The affected facilities included communities operated by well-known operators such as Brookdale Senior Living, Atria Senior Living, Sunrise Senior Living, and Five Star Senior Living.
Under the False Claims Act, a private whistleblower — called a “relator” — may file suit on the government’s behalf and receive between 15% and 25% of any recovery. At the midpoint of that range, Bassan’s relator share from the $440 million settlement could approach $88 million, making his award one of the more consequential individual relator recoveries to emerge from the long-term care pharmacy sector.
The 2026 Jury Verdict: A Record-Shattering Finding
In April 2026, after years of litigation, a federal jury returned a verdict that stunned the healthcare fraud enforcement community. The jury found Omnicare liable for 3,341,032 false claims and separately found that CVS — Omnicare’s parent company, which acquired it in 2015 — caused the submission of 1,016,039 of those claims. The jury awarded approximately $136 million in actual damages against Omnicare. Because the False Claims Act mandates treble damages, that figure automatically tripled to roughly $407 million. Added to $542 million in statutory penalties — calculated at a minimum of $5,000 per false claim — the total judgment reached $948,778,444.10, nearly $950 million.
The scale of the verdict placed the Omnicare CVS False Claims Act lawsuit in rare company. The DOJ publicly described it as “one of the largest damages verdicts rendered by a jury in a False Claims Act case” in the statute’s history. For context, most False Claims Act cases resolve through settlement well before trial; a jury verdict of this magnitude was extraordinary and immediately set the stage for the financial and legal upheaval that followed.
Key Facts and Timeline: Omnicare CVS False Claims Act Lawsuit at a Glance
| Event | Date | Key Detail |
|---|---|---|
| Whistleblower qui tam filing by Uri Bassan | 2015 | Filed on behalf of U.S. government, 29 states, and D.C. |
| Alleged scheme period | 2010–2018 | “Rolling over” prescriptions for 800,000+ LTC patients |
| Jury verdict — false claims found | April 2026 | 3,341,032 false claims; $948,778,444.10 total judgment |
| Omnicare Chapter 11 bankruptcy filing | September 22, 2025 | Unable to post appeal bond after verdict |
| GenieRx asset sale approved | May 13, 2026 | $250 million; buyer: Milrose Capital / Integro JV |
| DOJ $440M settlement announced | July 1, 2026 | CVS pays $130M immediately; $310M by March 15, 2028 |
| Disclosure/voting plan approved | August 12, 2026 | Judge Stacey G.C. Jernigan approves process |
| Bankruptcy wind-down plan — final approval | September 17, 2026 | “Overwhelming acceptance” from unsecured creditors |
For individuals seeking to understand how government enforcement actions intersect with potential personal claims, reviewing resources on the False Claims Act at Cornell’s Legal Information Institute provides an authoritative foundation on how the statute operates and who it protects.
Bankruptcy, the $440M Settlement, and What Happened to CVS
The $950 million judgment created an immediate crisis. Unable to post the bond required to pursue an appeal, Omnicare filed for Chapter 11 bankruptcy protection on September 22, 2025, in a Texas federal court. The proceeding moved quickly through 2026. In May, Bankruptcy Judge Stacey G.C. Jernigan approved the sale of Omnicare’s operating assets to GenieRx Holdings — a joint venture of Milrose Capital LLC and Integro Asset Management — for $250 million, ensuring that pharmacy services to long-term care facilities would continue under new ownership.
On July 1, 2026, Omnicare and CVS disclosed a $440 million settlement with the DOJ that resolved the government’s False Claims Act claims. Under the terms, CVS was required to pay $130 million within 14 days of the agreement’s effective date, with the remaining $310 million due by March 15, 2028. CVS stated that the settlement “is not an admission of liability or wrongdoing.” The settlement — while substantially less than the nearly $950 million verdict — still represents one of the largest False Claims Act resolutions in long-term care pharmacy history. CVS also separately settled a DOJ False Claims Act opioid-billing investigation for $315 million in October 2026, underscoring the breadth of federal scrutiny the company faced across its pharmacy operations.
On August 12, 2026, Judge Jernigan approved the disclosure and voting process for the Chapter 11 plan, and on September 17, 2026, she granted final approval of the wind-down plan after it received overwhelming acceptance from general unsecured creditors. The Omnicare CVS False Claims Act lawsuit was, at last, formally concluded.
What Nursing-Home Residents and Their Families Need to Know
For the families of elderly or disabled residents who lived in the more than 3,000 facilities allegedly touched by the “rolling over” scheme, the natural question is: do I have a claim? The answer requires careful understanding of what the False Claims Act does and does not do. The FCA is a government fraud statute — it protects the federal treasury and Medicare and Medicaid trust funds. It does not create a private right of action for individual nursing-home residents who received medications dispensed on stale prescriptions. Residents harmed by the administration of incorrect or unauthorized medications may, however, have separate civil claims under state law, including nursing-home negligence, medical malpractice, or elder abuse theories, depending on the facts of their case.
If a resident or family member believes that unauthorized prescription dispensing caused a physical injury — adverse drug reactions, falls linked to antipsychotic side effects, seizures from improperly continued anticonvulsants, or other documented harms — those facts may support a civil lawsuit entirely independent of the federal enforcement action. Using a medical malpractice calculator can help families begin to understand the potential value of injuries caused by unauthorized or negligently managed pharmaceutical care in a long-term care setting.
Families should also act promptly. State statutes of limitations for nursing-home negligence and medical malpractice vary significantly, and evidence — including pharmacy dispensing records and physician authorization logs — may be difficult to obtain as Omnicare completes its wind-down. Preserving medical records, requesting pharmacy dispensing histories, and consulting with an attorney experienced in elder care litigation are critical first steps. For broader injuries arising from systematic pharmaceutical misconduct, understanding how damages are calculated — including economic, non-economic, and potentially punitive components — is essential. A personal injury settlement calculator can provide families with an initial framework for assessing the range of compensation that may be available in a civil claim.
The Broader Implications for Long-Term Care Pharmacy Oversight
The Omnicare CVS False Claims Act lawsuit is more than a single case — it is a landmark moment for the regulation of long-term care pharmacy in the United States. For years, critics raised alarms about the structural incentives that large pharmacy benefit managers and long-term care pharmacies faced to continue filling prescriptions without rigorous authorization checks, particularly for elderly patients who could not advocate for themselves. The “rolling over” scheme alleged here — if true at the scale described — represents a systemic failure that touched millions of the most vulnerable Americans.
The case’s resolution sends a clear signal to the long-term care pharmacy industry: federal enforcement under the False Claims Act, supercharged by whistleblower qui tam filings from insiders like Uri Bassan, is an existential risk. The Centers for Medicare & Medicaid Services has long maintained compliance guidance for pharmacy billing, and this case illustrates what happens when those standards are allegedly abandoned at scale. GenieRx, as Omnicare’s successor, inherits both a substantial patient population and a heightened compliance obligation. Regulators, advocates, and families of nursing-home residents will be watching closely to ensure that the practices that generated the Omnicare CVS False Claims Act lawsuit are not repeated under new ownership.
For mass tort practitioners and legal observers, the case also illustrates the power and limits of the False Claims Act as a tool for addressing systemic healthcare fraud. The statute achieved a historic verdict and a $440 million recovery for the federal government. It did not, standing alone, compensate the individual patients who may have been harmed. Closing that gap — through state civil litigation, regulatory action, and enhanced oversight — remains the unfinished work of this landmark case.
Frequently Asked Questions: Omnicare CVS False Claims Act Lawsuit
What was the “rolling over” scheme at the center of the Omnicare CVS False Claims Act lawsuit?
“Rolling over” was an internal practice alleged by the DOJ in which Omnicare’s pharmacy computer system assigned new prescription numbers or reset refill counts — sometimes to as many as 99 — for Medicare patients whose prescriptions had expired or run out of authorized refills. This allowed pharmacists to continue dispensing medications, including antipsychotics, anticonvulsants, and antidepressants, without contacting the prescribing physician for a new order. The government alleged this practice generated millions of fraudulent claims billed to Medicare, Medicaid, and TRICARE, forming the core of the False Claims Act violation at issue in the case.
How large was the jury verdict in the Omnicare CVS False Claims Act lawsuit, and why was it so significant?
The April 2026 jury verdict found Omnicare liable for 3,341,032 false claims and found CVS caused an additional 1,016,039 claims. The jury awarded approximately $136 million in actual damages, which the False Claims Act automatically trebled to roughly $407 million. Combined with $542 million in statutory penalties, the total judgment reached $948,778,444.10 — nearly $950 million. The DOJ publicly called it “one of the largest damages verdicts rendered by a jury in a False Claims Act case,” making it a landmark in the history of federal healthcare fraud enforcement.
How did the Omnicare CVS False Claims Act lawsuit end, and how much did CVS pay?
Unable to post the appeal bond required after the verdict, Omnicare filed for Chapter 11 bankruptcy on September 22, 2025. Through the bankruptcy proceeding, Omnicare’s assets were sold to GenieRx Holdings for $250 million in May 2026. On July 1, 2026, Omnicare and CVS reached a $440 million settlement with the DOJ. CVS was required to pay $130 million within 14 days of the settlement’s effective date, with the remaining $310 million due by March 15, 2028. On September 17, 2026, Bankruptcy Judge Stacey G.C. Jernigan granted final approval of Omnicare’s wind-down plan, formally concluding the case.
Can nursing-home residents or their families file their own lawsuit related to the Omnicare CVS False Claims Act lawsuit?
The False Claims Act itself does not compensate individual patients — it protects the federal treasury and Medicare and Medicaid trust funds. However, residents or family members who can document that unauthorized prescription dispensing caused a physical injury — such as adverse drug reactions, falls, or other harm linked to improperly continued medications — may have separate civil claims under state law, including nursing-home negligence, medical malpractice, or elder abuse theories. These claims are independent of the federal enforcement action and are subject to state statutes of limitations, so acting promptly to preserve medical and pharmacy records and consult with legal counsel is critical.
Who was the whistleblower in the Omnicare CVS False Claims Act lawsuit, and what will he receive?
The whistleblower was Uri Bassan, a former Omnicare pharmacist who filed the original qui tam complaint in 2015 on behalf of the federal government, 29 states, and the District of Columbia. Under the False Claims Act, a relator who files a successful qui tam suit is entitled to receive between 15% and 25% of the government’s recovery. At the midpoint of that statutory range, Bassan’s share of the $440 million DOJ settlement could approach approximately $88 million — one of the more consequential individual relator awards to emerge from long-term care pharmacy enforcement in recent years.
This article is provided for general informational purposes only and does not constitute legal advice; individuals with potential claims related to the Omnicare CVS False Claims Act lawsuit or related nursing-home pharmacy misconduct should consult a licensed attorney in their jurisdiction.
Related reading: Nuclear Verdicts In Medical Malpractice: Why Jury Awards Are Exploding In 2026 & What It Means For Your Claim
Related reading: Locum Tenens Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Related reading: Diabetes Misdiagnosis Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.